Quebec City s Chainsawesome on upping the party game mayhem in Knight Squad 2 mobilesyrup.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mobilesyrup.com Daily Mail and Mail on Sunday newspapers.
Government lends its support toward development of compostable bioplastics
April 13, 2021
The Canadian government is backing innovations that encourage compostable bioplastics, and has made an investmen of $1 million to BOSK Bioproducts Inc. The Quebec City-based company will use the funding to explore the installation of a small-scale production line for proto-typing compostable bioplastics formulations made from forest biomass.
BOSK’s work represents the second phase of a bioplastics challenge geared towards helping small businesses turn forest-based residue into sustainable plastic materials, thereby reducing pollution. In the project’s first phase, BOSK developed a compostable and cost-effective new bioplastic made from paper mill sludge and wood fibre residue. This can be used in such applications as 3D printing, food packaging, plastic bottles and containers for cosmetics.
Exfo: Fiscal Q2 Earnings Snapshot
April 7, 2021
FacebookTwitterEmail
QUEBEC CITY (AP) Exfo Inc. (EXFO) on Wednesday reported a loss of $2.4 million in its fiscal second quarter.
On a per-share basis, the Quebec City-based company said it had a loss of 4 cents. Earnings, adjusted for amortization costs and non-recurring costs, came to 1 cent per share.
The telecommunications testing company posted revenue of $69.3 million in the period.
In the final minutes of trading on Wednesday, the company s shares hit $4.39. A year ago, they were trading at $2.91.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EXFO at https://www.zacks.com/ap/EXFO
Alithya to Acquire R3D Conseil and Sign C$600 Million in Commercial Agreements streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
MONTREAL Quebec City-based pharmaceutical developer Medicago has announced it’s ready to move forward with a phase three clinical trial of its COVID-19 vaccine candidate, after seeing “positive” interim results from phase two, the company said on Tuesday. An adjuvant or ‘booster’ produced by GlaxoSmithKline and administered along with the vaccine will also be studied. Both the U.S. Food and Drug Administration and Health Canada have approved the enrollment of up to 30,000 healthy adults worldwide, some of them in Montreal. We welcome phase 3 of @medicagoinc’s trials. has secured 20M doses w/ options for an additional 56M doses of their vaccine candidate - 1 of our 7 agreements.